Triple Negative Breast Cancer (TNBC) Clinical Trials in New York, New York

3 studies are recruiting for triple negative breast cancer (tnbc) in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

    This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical ([225Ac]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administe…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Icahn School of Medicine at Mt. Sinai, New York, New York
    Locations
    14 in total
    Run by
    Aktis Oncology, Inc.

    See if you can join NCT07020117 on ClinicalTrials.gov

  2. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

    Stage
    Not phased
    Ages
    18 and older
    Site
    NYU Langone Medical Center, New York, New York
    Locations
    16 in total
    Run by
    A2 Biotherapeutics Inc.

    See if you can join NCT04981119 on ClinicalTrials.gov

  3. Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

    The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    15 in total
    Run by
    Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

    See if you can join NCT05985655 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.